about
Structural insights into the association between BCAR3 and Cas family members, an atypical complex implicated in anti-oestrogen resistanceTolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.The cAMP signaling pathway as a therapeutic target in lymphoid malignancies.Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis.Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphomaChronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.AND-34/BCAR3 regulates adhesion-dependent p130Cas serine phosphorylation and breast cancer cell growth pattern.PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.BCAR3/AND-34 can signal independent of complex formation with CAS family members or the presence of p130Cas.CD40 ligand-mediated activation of the de novo RelB NF-kappaB synthesis pathway in transformed B cells promotes rescue from apoptosis.Characterization of AND-34 function and signaling.Preclinical assessment of curcumin as a potential therapy for B-CLL.Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells.Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis.Epstein-Barr virus-associated diffuse large B-cell lymphoma arising in atrial myxoma: a proposal for a modified therapeutic approach.Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin.Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.Anesthetic management for repair of Ebstein's anomaly.Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes.Pgp-1hi T lymphocytes accumulate with age in mice and respond poorly to concanavalin A.Chemotherapy as treatment for colo-colonic intussusception associated with acquired immune deficiency syndrome-related lymphoma.Cyclic AMP concentrations modulate both calcium flux and hydrolysis of phosphatidylinositol phosphates in mouse T lymphocytesInfliximab as a therapy for idiopathic hypereosinophilic syndromeVinca alkaloids vs. taxanes as therapy in lymphoid malignancies: do our experimental models obscure our understanding of how these drugs really work?Complete response of metastatic malignant hidradenocarcinoma to capecitabine treatmentGeneralized syringotropic mycosis fungoides responsive to extracorporeal photopheresisAnaplastic large cell lymphoma localized to the left breast years after radiotherapy for breast cancerSARS-CoV-2 Infection Associated Hemophagocytic Lymphohistiocytosis: An autopsy series with clinical and laboratory correlation.
P50
Q28304848-995E5F23-2CC2-47E3-8938-4F5BA2523A7EQ33417976-85702D78-8A5B-472E-8335-08470417035BQ33418737-86D2B7C0-78BA-4AE5-8919-A6D34ADA9E4FQ33865914-093B0BFB-2258-4A75-902A-8C8390C0FF9CQ34276482-6D040280-3B3E-483F-9741-A4C50F905091Q35096709-BB33A805-B0AD-4BC8-B18E-7BA82C927002Q36519044-E6F36A6E-316E-4F23-B218-7F7C3389E205Q37178775-1FA8C264-C75E-4139-9E30-4A7CB7B62BD4Q37339820-20CE3710-3026-4320-AB48-E158F66943EBQ38521299-F1BF8DD0-7EA8-4CA9-A279-AEC9C4EEDCE0Q38602496-41FE2F56-98B4-47FF-B1C5-89C4E0D2B7AFQ38956638-FCB324BB-2214-4720-9332-39380AE1CDDBQ39603673-A8F1A027-6284-410E-8CF2-806D9F3A9FC4Q40143589-13B2A135-22F6-4308-BA0D-CFEB827A19BDQ40270955-D827D17A-C3A3-4642-BA69-D77815D273ABQ42500786-B1912A57-6608-41A5-9CF8-BEDF7901A08FQ42942114-A09BBB25-7D58-4BAA-ACDB-63C71DE16178Q43225747-241ADD52-5552-4046-A012-072053F9414FQ44328887-86217205-2D66-4314-BF68-A41370B9141DQ45215634-C3849800-2444-4A94-A2A4-4980FCE8CE43Q45225362-036DD54B-7C88-464C-95E4-4B5C08CB62DEQ46032859-843B90D6-4E7F-4A24-8453-8CFA043EDD02Q50228613-72B57EF2-A78B-4A26-9FE3-F003AFED4EAEQ51300066-BAC80BC8-08D0-4A65-9221-4BA58C203E45Q51702528-A605A072-3324-4A42-893C-128F3672C701Q52115352-71509884-90E4-4C7C-9477-4D3FE714AA65Q53320762-1576E65F-D8E3-4B37-9821-EF20CAD77381Q69816807-25204B1E-F96E-4D91-88E5-88B575751A29Q81310603-29DA051B-C049-40EE-9B5C-BE9A541A7428Q81549876-394132FA-C6AC-4AB6-99FC-FE2A35F6D988Q84772358-E05D68C7-A296-4684-A902-CE9FBE5903E3Q87186533-EE63ED09-FC54-46A8-BFC4-E1BEE6570235Q95468514-0F979CD9-D279-426D-B63C-E8E0346FCDB0Q95608275-F91A1299-7DF0-4734-AFC6-9A7FC83AE499
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Adam Lerner
@ast
Adam Lerner
@en
Adam Lerner
@es
Adam Lerner
@nl
type
label
Adam Lerner
@ast
Adam Lerner
@en
Adam Lerner
@es
Adam Lerner
@nl
prefLabel
Adam Lerner
@ast
Adam Lerner
@en
Adam Lerner
@es
Adam Lerner
@nl
P106
P21
P31
P496
0000-0001-9259-7868